RecruitingPhase 4NCT05709626
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
Sponsor
Kindai University
Enrollment
2,258 participants
Start Date
Feb 28, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)
- STEMI patients
- Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months
Exclusion Criteria4
- Patients taking anticoagulants
- Patients under 18 years old
- Patients with less than 1 year prognosis
- Patients participating in other intervention studies
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNo aspirin (Prasugurel monotherapy)
12-month prasugrel monotherapy
DRUG12-month DAPT
12-month dual antiplatelet therapy with prasugrel and aspirin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05709626
Related Trials
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention
NCT075368022 locations
Systemic Organ Communication in STEMI
NCT035391331 location
Using Cardiac MRI to Predict Outcomes in Patients With STEMI
NCT070728581 location
Early Beta Blocker Administration in STEMI Patients With SCAI B Status
NCT069671941 location
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
NCT067692561 location